Searchable abstracts of presentations at key conferences in endocrinology

ea0029p398 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Endocrine hypertension due to primary aldosteronism

Rodrigues P. , Mesquita J. , Souto S. , Belo S. , Morgado P. , Varela A. , Castedo J. , Magalhaes , Carvalho D.

Introduction: Primary aldosteronism (PA) is currently believed to be the most frequent form of secondary endocrine hypertension, accounting for 5–10% of all hypertensive patients. After confirming the diagnosis, adrenal venous sampling (AVS) is considered the most accurate means of distinguishing between unilateral and bilateral adrenal disease.Case report: Female patient, 36 years-old, referred to an Endocrinology appointment in May 2009 due to lef...

ea0029p1504 | Pituitary Clinical | ICEECE2012

Hyperprolactinemia: prolactinoma or pregnancy?

Belo S , Magalhaes A , Carvalho D

Introduction: High prolactin levels may have several etiologies including the presence of a prolactin producing pituitary adenoma or the treatment with drugs of different classes. Certain physiological states, from which pregnancy stands out, are also characterized by elevated levels of prolactin.Case: Woman, 28 years old, with no relevant medical history or chronic medication apart from oral contraceptives, begins with amenorrhea in May 2010, without ga...

ea0026p654 | Clinical case reports | ECE2011

Type II polyglandular syndrome: a case report

Belo S , Magalhaes A , Carvalho D

Introduction: The combination of two or more, autoimmune, endocrine dysfunctions defines the presence of polyglandular syndromes.Case report: Female patient, 43 years old, history of type 1 diabetes for 23 years and autoimmune hypothyroidism for 7 years, with no other relevant clinical history and without family history of autoimmune endocrinopathies. She was under therapy with insulin and levothyroxine. She came into the Endocrinology Department in May ...

ea0029p115 | Adrenal medulla | ICEECE2012

Pheochromocytomas: a single centre experience

Belo S. , Magalhaes A. , Nogueira C. , Carvalho D.

Introduction: Catecholamine-secreting tumors (pheochromocytomas and paragangliomas) are rare intra and extra-adrenal neoplasms, probably occurring in less than 0.2% of patients with hypertension. Serious morbidity and mortality rates are associated with these tumors which are related to the effects of catecholamines on various organs, especially those of the cardiovascular system.Methods: We reviewed the cases of pheochromocytomas and paragangliomas that...

ea0029p693 | Diabetes | ICEECE2012

Variations in insulin daily dose and weight with continuous subcutaneous insulin infusion therapy

Belo S. , Esteves C. , Pereira M. , Neves C. , Carvalho D.

Introduction: Intensive diabetes type 1 management can be achieved either with multiple daily insulin injection therapy or with continuous subcutaneous insulin infusion (CSII). The former is becoming increasingly popular do to its positive effects on glycemic control.Objectives: Evaluate the evolution of total daily insulin dose (TDID) and weight on patients with CSII.Methods: Patients with CSII of our department were included. Dat...

ea0029p100 | Adrenal cortex | ICEECE2012

Exogenous corticosteroids: guilty or innocent?

Matos M. , Freitas P. , Belo S. , Frazao J. , Pimenta T. , Guimaraes S. , Carvalho D.

Introduction: The association between autoimmune diseases, including systemic lupus erythematosus (SLE), and endogenous hypercortisolism is rare. The latter is usually misinterpreted as iatrogenic in the case of patients taking exogenous systemic corticosteroid therapy. The excess endogenous glucocorticoids may play an important role in suppressing autoimmune activity. Similarly, the abrupt resolution of endogenous hypercortisolism may lead to a rebound worsening of autoimmuni...

ea0029p718 | Diabetes | ICEECE2012

Gender differences in metabolic outcomes of continuous subcutaneous insulin infusion therapy

Esteves C. , Neves M. , Belo S. , Pereira M. , Sousa Z. , Carvalho D.

Introduction: The continuous subcutaneous insulin infusion (CSII) is an alternative to multiple daily injection therapy in type 1 diabetes and its use is increasingly common due to the beneficial effects on the glycemic control of the patient.Aims: To find differences on outcomes of CSII therapy between genders. Patients and methods: Patients on CSII therapy in our department were included in the study and we recorded outcomes regarding the following set...

ea0029p1363 | Pituitary Clinical | ICEECE2012

Familial isolated pituitary adenoma: review of four families

Belo S. , Mesquita J. , Nogueira C. , Magalhaes A. , Basto M. , Pereira J. , Carvalho D.

Introduction: Pituitary adenomas are frequent brain tumors, with prevalence of about 1:1000. Most occur sporadically. The familial forms represent 5% of cases. These can be found associated with other endocrine neoplasia (MEN 1, Carney complex, MEN 4) or as a clinical isolated entity – FIPA. This is characterized by the presence of pituitary tumors in two or more family members, in the absence of features of other endocrine syndromes. AIP gene mutation, which may or may n...

ea0026p653 | Clinical case reports | ECE2011

Maltose interference in the determination of blood glucose levels by test strips based on glucose dehydrogenase-PQQ method: a case report

Belo S , Rodrigues P , Alves M , Neves C , Magalhaes A , Carvalho D

Background: The different systems for monitoring capillary blood glucose levels may suffer interference from various substances.Case report: Male patient, 48 years old, with history of hypertension, dyslipidemia and previous smoking. He presented also type 1 diabetes mellitus, with 37 years of progress, with diabetic retinopathy, kidney failure, in peritoneal dialysis since 2009, and ischemic heart disease (myocardial infarction in 2005). He was treated ...

ea0026p610 | Clinical case reports | ECE2011

Cholestatic jaundice methimazole-induced or secondary to heart failure?

Souto S B , Rodrigues P , Belo S , Nogueira C , Magalhaes A , Castedo J L , Carvalho-Braga D , Carvalho D

Methimazole-induced cholestatic jaundice is a rare adverse effect, dose-dependent, occurring within the first 3 months of use, usually reversible within 3 months after discontinuing drug therapy.Case report: Woman, 64 years, history of hyperthiroidism since August 2009, under therapy with methimazole 5 mg/day. The patient was referred to endocrinology department in March 2010, with history of heart failure, atrial fibrillation, type 2 diabetes mellitus, ...